Connect with us

MARKETS

Kush Bottles Inc (OTCMKTS:KSHB) Unveils Innovative Labeling Services

Published

on

Kush Bottles Inc (OTCMKTS:KSHB) has introduced an innovative printing, labeling, and in-house application services to shorten the production time. It also prevents the dependency on multiple suppliers for the customers and become a full service company to fulfill the commitment.

The company is now able to meet all of the customer packaging needs using its own tools, equipment, and materials.

The new labeling technology and capabilities now eliminate the labor involved in a variety of glass jars and pop-tops without affecting the quality of the labels. It also reduces the UV printing production lead times to almost half. It has also significantly lowered the minimum order quantity for the customers.

New machines installed at Kush Bottles Inc are Epson Large Format printer, Vanguard Digital Flatbed UV Printer, Industrial Label Finishers, Summa Flatbed Finisher, Custom Label Application Equipment, and Industrial Color Label Printers.

Kush Bottles Inc Announces Hiring of Director (Production)

Kush Bottles Inc has appointed Mike Alejos as Director (Production) to head the new labeling line. He is working from the day one of joining the company to implement new processes and helps efficient usage of the investments to improve product delivery.

Mr. Alejos is skilled in custom cannabis packaging solutions. During his role as an operator/ owner of The Label Plugs, he performed exceptionally to meet the customized packaging needs of more than 250 cannabis businesses.

Chief Executive Officer of Kush Bottles Inc, Nick Kovacevich said the addition of new labeling capabilities projects the company as a one-stop solution for packaging needs for the quick turnaround. He further said, Kush Bottles Inc is adding more value and improving the scale of customers in a cost-effective way by diversifying the offerings on a continuing basis. The company is able to significantly reduce the turnaround time for the customers. Therefore, it reduces the product time to market and reaps rich dividends.

Kush Bottles Inc Completes Registered-Direct-Offering of 7.5 Million Shares and Warrants

Kush Bottles Inc has announced completing registered direct offering of 7.5 million shares and warrants. The warrants can be exercised at a strike price of $5.28 for each share. The validity of warrants is up to 5 years from the date of issuance. The company intends to issue the proceeds of $36 million for general corporate purposes.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

BetterLife Pharma Inc (OTCMKTS:PVOTF) Readies Interferon Alpha-2b To Clear Caronavirus From The Airways Of Patients

Published

on

BetterLife Pharma Inc (OTCMKTS:PVOTF) expects to publish results of the third-party study of the drug – Interferon Alpha-2b in the journal Frontiers of Immunology this Friday. The company has examined the effectiveness of Interferon Alpha-2b on seventy-seven Wuhan based patients infected with moderate to severe coronavirus during January 16 and February 20, 2020. According to the study, the drug can effectively clear the coronavirus from the airways of affected patients.

An unexplored and uncontrolled study is conducted on seventy-seven patients in Wuhan by administering arbidol (200 mg t.i.d.) or nebulized IFN-α2b (5 mU b.i.d.) or a combination of both. In the trial, temperature, serum cytokine levels, blood chemistry, cell counts, and blood oxygen saturation levels are recorded. Interferon Alpha-2b has effectively reduced coronavirus duration either with or without arbidol in the upper respiratory tract. Further investigation is required on IFN-α2b to treat COVID-19.

Should give priority for clinical trials of Interferon Alpha-2b

The study is featured in the Canadian national newspaper – Globe and Mail in its May 13, edition under the article title ‘Interferon emerges as a potential treatment for COVID-19’. A researcher at Toronto University Health Network – Dr. Eleanor Fish said the awareness about this drug to treat coronavirus is slow and should give priority for the clinical trials on a large scale.

Interferons to treat coronavirus infections

According to Fish, interferons provide the first line of defense against all the viruses. However, viruses like coronavirus have evolved to block the response of interferon. It necessitates the need for interferons to treat coronavirus infections.

The new drug of BetterLife Pharma overrides the inhibitory effects of COVID-19. Fish said that instead of developing a virus-specific antiviral every time, it is better to consider interferons for the treatment of viruses like coronavirus.

Interferons have already received the nod to treat viral infections several years back. It is now time to repropose them to treat moderate to severe virus infections. Therefore, a large clinical trial involving Interferon Alpha-2b on a cohort of patients further supports the research.

CEO of BetterLife Pharma, Ahmad Doroudian, said the company is pleased with the results of a recently concluded study in using Interferon Alpha-2b to treat COVID-19. The outcome supports BetterLife’s approach to treating coronavirus. Ahmad said he supports the view of Fish and further excited by the recent study results.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

MARKETS

CV Sciences Inc (OTCMKTS:CVSI) Navigates Market Storms

Published

on

Any company that faces the campaign of short sellers experiences hard times; especially the shareholders. In the recent months, CV Sciences Inc (OTCMKTS:CVSI) had a rough battle with the investors which badly bruised the share price. In an Aug. 30, 2018 press statement, the company gave an update to shareholders regarding the situation.

In the update, CV Sciences acknowledges the “malicious” intent of the short sellers. The company CEO, Joseph Dowling further explains that they are victims of “campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls.”

Manipulations

The CEO further details that: “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”

In rebuttal, the CEO affirms that the company presents strong financial numbers and that this will go on in future. He adds that there is nothing different with the business model since it is solid. Joseph speaks out so strongly about the “manipulations” and offers his sympathy for the shareholders.

“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts,” he says.

A product milestone for CV Sciences Inc (OTCMKTS:CVSI)

The run in with the short sellers did not dampen the company’s spirits. In under two weeks, the company announced a great milestone for one of its products. The PlusCBD Oil™ Gold Formula product line acquired the Generally Recognized as Safe (GRAS) status. The status implies successful performance on the safety front. Further, the GRAS status implies the U.S. Food and Drug Administration (FDA) approves of the production and supply of PlusCBD Oil™.

Such a status is important to product sales and consumer confidence in the company. Concurring with the assessment, the CEO says:

“We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Tilray (TLRY) Joins Cannabis Sector’s Pause, Which Is Good News For People Who Missed Its July IPO

Published

on

With the high-flying cannabis sector taking a pause, now is the time for investors to reassess their positions.

A good place to start would be by taking a moment to examine who is guiding cannabis-focused companies. In other words, who is it that is forming a company’s reputation.

Take, for example, high-flying Tilray, Inc. (TLRY). It’s a pioneer in medical cannabis research, cultivation, processing, and distribution. Now it is rapidly staking a strong place in Canada’s soon-to-be legal adult marijuana market.

Looking beyond its world-class research teams, investors will discover Tilray has one of the sector’s most prestigious board of directors.

Tilray’s board includes Rebekah Doop, who is a principal at Google. Then there’s Scotty Greenwood, who was chief of staff sat the U.S. Embassy in Canada, and is now the CEO of the Canadian American Business Council.

Of course, the board itself is not solely responsible for the 400 percent run up since Tilray’s July IPO. Still, it should comfort investors to know Tilray is in such good hands.

Doop and Greenwood are joined on the board by other corporate heavyweights, such as Christine St. Claire, who was a principal and lead audit partner at KPMG; Michael Auerbach, a risk expert who has held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution.

Rapid Expansion Into Legalized Pot

Based in British Columbia, Canada, Tilray is global concern. It is the only GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments, and researchers in 11 countries on five continents.

It’s also perfectly positioned in the heart of Canada’s legalized cannabis industry.

The Prince Edward Island Cannabis Management Corporation recently selected a Tilray subsidiary to supply its adult-use cannabis.

The purchase order will allow its wholly owned affiliate, The High Park Company, to supply PEI’s four cannabis stores and online channels with cannabis products. It’s all in anticipation of the launch of the adult-use market on October 17, 2018.

In all, Tilray has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories, including British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory, and the Northwest Territories

Its subsidiary, High Park, is Toronto-based, and is led by a team with deep experience in cannabis and global consumer brands.

Tilray established High Park in order to develop, sell, and distribute a broad-based portfolio of adult-use cannabis brands and products. Its portfolio is uniquely crafted and grown by master horticulturists dedicated to sustainable growing practices.

Tilray’s shares were downgraded Northland Capital, which gave “complex valuations” as the basis of its esoteric reasoning. Tilray’s share price shed nearly 11 percent on the news.

But Tilray is a strong company.

It has a partnership to develop medical products with Sandoz Canada, a division of Novartis (NVS). Tilray also has a relationship with Privateer Holdings and marijuana information website Leafly, along with distribution deals with Shoppers Drug Mart, Pharmasave and various Canadian provinces.
It is perfectly posi

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories